9119 Gaither Road
Gaithersburg, MD 20877
United States
301 825 9810
https://www.neximmune.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 6
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Ms. Kristi Jones R.Ph. | CEO, President & Director | 989,28k | N/A | 1963 |
Dr. Mathias Oelke Ph.D. | Chief Scientific Officer | 605,78k | N/A | 1968 |
Mr. John Trainer M.B.A. | Consultant | 1,33M | N/A | 1974 |
Mr. Albert Nicholas Marchio II | Interim CFO & Principal Accounting Officer | N/A | N/A | 1952 |
Mr. Karen Haslbeck | Head of Human Resources | N/A | N/A | N/A |
Dr. Daniel P. Bednarik | Senior Vice President of Molecular Engineering & Protein Design | N/A | N/A | N/A |
Dr. Robert Douglas Knight M.D. | Chief Medical Officer | 454,77k | N/A | 1951 |
Mr. Chad Rubin | Senior Vice President of Corporate Affairs | N/A | N/A | N/A |
Dr. Jack A. Ragheb M.D., Ph.D. | Senior Vice President of Translational Science | N/A | N/A | N/A |
Mr. Matthew Schiller | Head of Business Development | N/A | N/A | N/A |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
NexImmune, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 8, Kompensation: 10.